RSV vaccine protection wanes for some nursing home residents CHICAGO — A study of nursing home residents demonstrated that vaccination against respiratory syncytial virus reduced their risk for illness, although protection waned over time for some.Researchers measured the protective impact of Abrysvo, Pfizer’s RSV vaccine, among 15,078 residents living in Veterans Health Administration nursing homes over the course of two seasons.

🚨A study presented at #SHEA2026 revealed that an #RSVvaccine 💉 showed a “meaningful reduction” of illness risk. Read here ⬇️

vist.ly/4xu9h

Pfizer RSV Vaccine Offered to 3M in England Pfizer's RSV vaccine offered to 3.0m older adults in England on Apr 2, 2026, representing ~25% of the 65+ cohort and signalling a key public-sector procurement test.

Pfizer RSV Vaccine Offered to 3M in England: Pfizer's RSV vaccine offered to 3.0m older adults in England on Apr 2, 2026, representing ~25% of the 65+ cohort and signalling a key public-sector procurement test. 👈 Read full analysis #Pfizer #RSVVaccine #Vaccination #PublicHealth #Immunization

Got my #RSVVaccine yesterday.

#RSVvaccine is proving valuable; it may not just prevent RSV but also decrease #asthma incidence in children. RFK will not allow it. US citizens are being killed by ICE & will suffer from
chronic diseases because medical care is unaffordable/unavailable

Rating Risk of Cardiac Events after RSV in Older Adults | Contagion Live Risk of a cardiac event was higher in older patients hospitalized for respiratory syncytial virus (RSV) infection than has been reported for influenza.

#RSVawareness #PreventRSV #RSVvaccine #MedicallyVulnerable #ChronicIllness #ProtectOurSeniors #PublicHealth #GetVaccinated #Vaccinations #StaySafe #MEDsky

*Rating Risk of Cardiac Events after RSV in Older Adults | Contagion Live

2-9-26
www.contagionlive.com/view/rating-...

I suppose one day the app that sends out invites for vaccines will be able to read the app that records that we’ve already had them.

Must be confusing for those who can’t remember whether they went, or think they need another one.

#NHS
#RSVVaccine

CHMP decision levels the playing field for GSK's RSV jab GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

#vaccines #immunisations #CHMP #GSK #RSVvaccine #respiratorysyncytialvirus #respiratorysyncytialvirusvaccine #RSV #Arexvy #labelexpansion #CHMPrecommendation #Pfizer #Abrysvo #Moderna #mResvia #lowerrespiratorytractdisease #LRTD #RSVdisease #RSVinfections #infectiousdiseases
zurl.co/PkV03

Emma Walmsley upholds £40B sales target in her final GSK CEO report Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter. | Emma Walmsley and her ...

#GSK #EmmaWalmsley #LukeMiels #Blenrep #Arexvy #Shingrix #multiplemyeloma #PD1inhibitor #Jemperli #rectalcancer #antibodydrugconjugates #ADCs #HansohPharma #FDAapproval #longactingbiologic #depemokima #chronicrhinosinusitis #biologics #vaccines #shinglesvaccine #RSVvaccine
zurl.co/iumHW

Learn about Those Nerdy Girls and its mission, and about the #RSVvaccine, from Nerdy Girl Gretchen.
www.youtube.com/watch?v=T4EI...

WTF Wire

Prepare for the 2025-26 #respiratoryvirusseason. Learn who should get vaccinated against Covid-19, flu, and RSV, where to get shots, and the best timing. #WTFWire #FluShot #RSVVaccine #HealthAwareness #Immunization #FluSeason2025 #Covid19Prevention #RSVPrevention www.wtfwire.com/health/2025-...

Western states band together to make Covid vaccines available side by side with flu and RSV. Read the full article on Monterey County Now.

Western states band together to make Covid vaccines available side by side with flu and RSV. #covidvaccine #fluvaccine #rsvvaccine #california #oregon #washington #hawaii #westcoasthealthalliance #vaccinerecommendations

RSV: When It's More Than Just a Cold Almost all children get RSV at least once before they are 2 years old. For most healthy children, RSV is like a cold. But some children get very sick with RSV. Learn the symptoms and how to protect yo...

"RSV is one of the many viruses that cause respiratory illness. It spreads like a cold virus from person to person."

#RSV #RSVVaccine #RSVImmunization

healthychildren.org/English/heal...

How effective is the RSV vaccine for older adults? A single dose of the RSV vaccine offers 58% protection against hospitalization in older adults, but effectiveness varies in immunocompromised individuals.

How effective is the RSV vaccine for older adults? 💉🧓 #JAMAStudy
www.news-medical.net/news/2025090...
#RSVVaccine #PublicHealth #Immunization #Vaccine

One shot of RSV vaccine effective against hospitalization in older adults for two seasons – BioNews Central One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons. ...

One shot of an #RSVVaccine protects adults aged 60 and older from RSV-associated #hospitalization and #CriticalIllness for two consecutive #RSV seasons. 
#OlderAdults #RespiratorySyncytialVirus #RSVVaccination

Vaccines Weekly Update – August 14th 2025 🔬💉 Vaccine Breakthroughs: mRNA Settlements, Cancer Vaccine Trials, RSV Effectiveness & More   This week’s Vaccine Research roundup brings you […] The post Vaccines Weekly Update – August 14th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Vaccines Weekly Update – August 14th 2025 #News #InfectiousDiseases #cancervaccine #RSVVaccine Comment below!

Vaccines Weekly Update – August 14th 2025 🔬💉 Vaccine Breakthroughs: mRNA Settlements, Cancer Vaccine Trials, RSV Effectiveness & More   This week’s Vaccine Research roundup brings you […] The post Vaccines Weekly Update – August 14th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Vaccines Weekly Update – August 14th 2025 #News #InfectiousDiseases #cancervaccine #RSVVaccine Comment below!

Vaccines Weekly Update – August 14th 2025 🔬💉 Vaccine Breakthroughs: mRNA Settlements, Cancer Vaccine Trials, RSV Effectiveness & More   This week’s Vaccine Research roundup brings you […] The post Vaccines Weekly Update – August 14th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Vaccines Weekly Update – August 14th 2025 #News #InfectiousDiseases #cancervaccine #RSVVaccine Comment below!

What’s the plan for fall vaccines? If you're confused, you're not alone. The dominoes have stalled, which can turn out to be a big problem.

Nothing is normal about U.S. vaccine rollouts for this fall & winter. Start figuring out your strategy to protect you & your loved ones — good advice here:

open.substack.com/pub/yourloca...

#COVID
#FluVaccine
#RSVVaccine

Vaccines Weekly Update – July 18th 2025 🔬💉 Vaccines Global Breakthroughs: Clinical Updates From India to the EU and More 🌍💉🧬 In this week’s edition of Vaccine […] The post Vaccines Weekly Update – July 18th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Vaccines Weekly Update – July 18th 2025 #News #Moderna #RSVVaccine #vaccineresearch Comment below!

Vaccines Weekly Update – July 18th 2025 🔬💉 Vaccines Global Breakthroughs: Clinical Updates From India to the EU and More 🌍💉🧬 In this week’s edition of Vaccine […] The post Vaccines Weekly Update – July 18th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Vaccines Weekly Update – July 18th 2025 #News #Moderna #RSVVaccine #vaccineresearch Comment below!

Vaccines Weekly Update – July 18th 2025 🔬💉 Vaccines Global Breakthroughs: Clinical Updates From India to the EU and More 🌍💉🧬 In this week’s edition of Vaccine […] The post Vaccines Weekly Update – July 18th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Vaccines Weekly Update – July 18th 2025 #News #Moderna #RSVVaccine #vaccineresearch Comment below!

GSK seeks FDA nod for expanded use of RSV vaccine in adults (Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age of 50 at a higher risk of the disease. If approved in the world’s biggest pharmaceuticals market, GSK’s vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna (NASDAQ:MRNA)’s mRESVIA and Pfizer (NYSE:PFE)’s Abrysvo. RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults. GSK’s vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59. While it had a lead in approvals initially, it has since lagged behind rivals and sales have fallen sharply. The FDA is expected to make a decision on the expanded use of Arexvy in the first half of 2026, GSK said. European regulators are also expected to rule on a similar application by then. With GSK making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed GSK alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including GSK, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is GSK poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #GSK #RSVVaccine #FDAApproval #Healthcare #Pharmaceuticals

GSK seeks FDA approval to expand RSV vaccine use to younger adults Investing.com -- British drugmaker GSK (NYSE:GSK) has submitted an application to the U.S. Food and Drug Administration (FDA) to extend the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults under the age of 50 who are at higher risk of the disease. The company announced the submission on Monday. Arexvy is currently approved for older adults, and this application aims to make the vaccine available to a younger population with elevated risk factors for RSV. RSV is a common respiratory virus that can cause serious illness, particularly in vulnerable populations. The application represents GSK’s effort to broaden protection against RSV to additional at-risk groups. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is GSK one of them?

Click Subscribe #GSK #FDAApproval #RSVVaccine #Arexvy #Vaccination

GSK applies to expand RSV vaccine use to adults 18 and up in EU Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #GSK #RSVVaccine #Healthcare #EUHealth #Vaccines

Infant hospitalizations from RSV dropped after shots became available, US data shows The U.S. Centers for Disease Control and Prevention in a report on Thursday said that hospitalizations related to RSV decreased by 28% and 43% across two large national databases, compared to pooled rates from 2018-2020. The 2024-2025 season marked the first period of widespread availability of preventive shots against RSV, a virus that often results in cold-like symptoms but is a major cause of severe infection and death in infants and older adults.

Infant hospitalizations from RSV dropped after shots became available, US data shows
#RSVvaccine
www.yahoo.com/news/infant-hospitalizat...

ISPOR, Subscriptions, RSV Vaccine | GameFi News ISPOR, subscriptions, RSV vaccine explained! Healthcare's future, decoded for you. Beginner's guide.

LifeNextDaily News!
🚀 Navigating healthcare's future? Demystifying ISPOR, health subscriptions & RSV vaccines for smarter, healthier living. Get informed!#ISPOR #Healthcare #RSVvaccine

Click here↓↓↓

New RSV vaccine, treatment linked to dramatic fall in baby hospitalizations Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published today...

New RSV vaccine, treatment linked to dramatic fall in baby hospitalizations #Technology #Other #RSVVaccine #ChildHealth #HealthcareInnovation

@uriebay.bsky.social @beyerstein.bsky.social @tomlevenson.bsky.social @anniegirl.bsky.social @doloresquintana.bsky.social @merlinofcanada.bsky.social @maej43.bsky.social Hallelujah!😡 #Saskatchewan is actually doing something right.😌 #RSVVaccine Now about the rest of the provinces...🤔

Sask. expanding infant RSV immunization program | CBC News Saskatchewan is expanding its infant RSV immunization program to include all babies born one month before and during RSV season, which typically lasts from the start of October until the end of March.

Sask. expanding infant RSV immunization program #Saskatchewan #RSVVaccine

All babies born during RSV season, or 1 month before, will now be eligible for vaccine

www.cbc.ca/news/canada/...

GSK resolves patent lawsuit against Pfizer over RSV vaccines By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline (NYSE:GSK) and rival Pfizer (NYSE:PFE) have agreed to end a lawsuit that alleged Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK’s patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court. GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled. Spokespeople for the companies did not immediately respond to requests for comment and more information, including whether the case was settled. GSK, Pfizer and Moderna (NASDAQ:MRNA) have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK’s Arexvy responsible for the majority of U.S. RSV vaccine sales. The respiratory disease typically causes cold-like symptoms, but it is also a leading cause of pneumonia in toddlers and older adults. GSK sued Pfizer in 2023, arguing that the New York-based company’s vaccine infringed GSK patents related to antigen technology. GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot. GSK has also sued Pfizer for patent infringement in the U.S. over technology in Pfizer’s blockbuster COVID-19 vaccine Comirnaty. That case is still ongoing.

Click Subscribe #GSK #Pfizer #RSVvaccine #patentlawsuit #pharmaceuticals